Olaparib Dosage Can Be Reduced Without Affecting Survival in Ovarian Cancer
April 18, 2022 12:28 pmby Lindsay Fischer
New research suggests that olaparib treatment interruption or dosage reduction is not linked with inferior survival outcomes in patients with BRCA1/2–mutated, platinum-sensitive, recurrent ovarian cancer.
Patients with BRCA1/–mutated, platinum-sensitive, recurrent ovarian cancer who needed to reduce